Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers.

Ramirez K, Wahid R, Richardson C, Bargatze RF, El-Kamary SS, Sztein MB, Pasetti MF.

Clin Immunol. 2012 Aug;144(2):98-108. doi: 10.1016/j.clim.2012.05.006.

PMID:
22710446
2.

Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.

Sundararajan A, Sangster MY, Frey S, Atmar RL, Chen WH, Ferreira J, Bargatze R, Mendelman PM, Treanor JJ, Topham DJ.

Vaccine. 2015 Jan 15;33(4):568-76. doi: 10.1016/j.vaccine.2014.09.073.

3.

A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.

Periwal SB, Kourie KR, Ramachandaran N, Blakeney SJ, DeBruin S, Zhu D, Zamb TJ, Smith L, Udem S, Eldridge JH, Shroff KE, Reilly PA.

Vaccine. 2003 Jan 17;21(5-6):376-85.

PMID:
12531635
4.

Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, Bargatze RF, Sztein MB, Tacket CO.

J Infect Dis. 2010 Dec 1;202(11):1649-58. doi: 10.1086/657087. Erratum in: J Infect Dis. 2011 Apr 1;203(7):1036.

5.

Mucosal and Cellular Immune Responses to Norwalk Virus.

Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, Atmar RL.

J Infect Dis. 2015 Aug 1;212(3):397-405. doi: 10.1093/infdis/jiv053.

6.

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.

Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF.

Eur J Immunol. 2008 Jan;38(1):114-26.

7.

TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.

Hjelm BE, Kilbourne J, Herbst-Kralovetz MM.

Hum Vaccin Immunother. 2014;10(2):410-6. doi: 10.4161/hv.27147.

8.

An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.

Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM.

Clin Vaccine Immunol. 2010 Dec;17(12):1850-8. doi: 10.1128/CVI.00230-10.

9.

Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes.

Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ.

J Infect Dis. 2000 Jul;182(1):302-5.

PMID:
10882612
10.

Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein.

Zhang X, Buehner NA, Hutson AM, Estes MK, Mason HS.

Plant Biotechnol J. 2006 Jul;4(4):419-32.

11.

Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.

Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK.

Gastroenterology. 1999 Jul;117(1):40-8.

PMID:
10381908
12.

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK.

Clin Immunol. 2003 Sep;108(3):241-7.

PMID:
14499247
14.

T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route.

Lehner T, Brookes R, Panagiotidi C, Tao L, Klavinskis LS, Walker J, Walker P, Ward R, Hussain L, Gearing JH, et al.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8638-42.

15.

Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets.

Cherukuri A, Servat E, Woo J.

Vaccine. 2012 Jan 5;30(2):237-46. doi: 10.1016/j.vaccine.2011.11.001.

PMID:
22080173
16.

Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses.

Huang Z, Elkin G, Maloney BJ, Beuhner N, Arntzen CJ, Thanavala Y, Mason HS.

Vaccine. 2005 Mar 7;23(15):1851-8.

PMID:
15734055
17.

Antibody prevalence and immunoglobulin IgG subclass pattern to Norwalk virus in Sweden.

Hinkula J, Ball JM, Löfgren S, Estes MK, Svensson L.

J Med Virol. 1995 Sep;47(1):52-7.

PMID:
8551259
18.

Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen.

Lehner T, Tao L, Panagiotidi C, Klavinskis LS, Brookes R, Hussain L, Meyers N, Adams SE, Gearing AJ, Bergmeier LA.

J Virol. 1994 Mar;68(3):1624-32.

19.

Chimpanzees as an animal model for human norovirus infection and vaccine development.

Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, Engle R, Yu C, Kapikian AZ, Sosnovtsev SV, Purcell RH, Green KY.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):325-30. doi: 10.1073/pnas.1014577107.

20.

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.

Vaccine. 2011 Sep 16;29(40):7009-19. doi: 10.1016/j.vaccine.2011.07.033.

PMID:
21787825

Supplemental Content

Support Center